老年人心源性院外心脏骤停的无血流时间与结局
这项日本全国多中心回顾性队列研究纳入259 851例≥65岁目击心源性OHCA患者,无血流时间中位11分钟,3.4%达到30天良好神经结局(CPC 1-2)。动态概率曲线显示,良好神经结局概率降至1%以下的无血流时间阈值随年龄递增而缩短:65-74岁14分钟、75-84岁11分钟、85-94岁2分钟、≥95岁0分钟。结果提示无血流时间窗随年龄增长而收窄,可辅助老年人群复苏决策。
要点
- ≥65岁目击心源性OHCA:无血流时间中位11分钟,30天良好神经结局(CPC 1-2)仅3.4%。
- 良好神经结局概率<1%的无血流时间阈值:65-74岁14分钟,75-84岁11分钟,85-94岁2分钟,≥95岁0分钟。
- 全部≥65岁患者对应阈值为11分钟(95%CI 11-11)。
- 随年龄增长,可达到≥1%良好神经结局概率的无血流时间窗进行性缩短。
- 该阈值基于回顾性观察数据,可用于复苏决策参考,非前瞻性验证的决策 cutoff。
适用人群与场景
- 日本全国EMS系统内、≥65岁、目击心源性院外心脏骤停并接受EMS启动CPR的成人患者。
诊断标准与关键阈值
- 无血流时间定义为目击心脏骤停至EMS人员启动CPR的间隔。
- 主要结局为30天良好神经结局,定义为脑功能分类(CPC)1或2。
- 按年龄分层(65-74、75-84、85-94、≥95岁)构建动态概率曲线,识别估计概率<1%对应的无血流时间。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:全国性、人群基础、多中心回顾性观察队列研究;数据源All-Japan Utstein Registry。
- 样本量:1 795 502例登记病例中259 851例符合纳入标准;中位年龄82岁(IQR 75-88),男148 018例(57.0%),中位无血流时间11分钟(IQR 8-15)。
- 主要终点:30天良好神经结局(CPC 1-2)8711例(3.4%)。
- 良好神经结局概率<1%的无血流时间阈值:全部≥65岁11分钟(95%CI 11-11);65-74岁14分钟(95%CI 14-14);75-84岁11分钟(95%CI 10-11);85-94岁2分钟(IQR 0-4);≥95岁0分钟(95%CI 0-0)。
证据类型、等级与局限
- 证据类型:回顾性观察性队列研究(非RCT),原文未给出证据等级或推荐强度。
- 局限:回顾性设计、观察性关联、阈值基于模型估计的概率曲线,需前瞻性验证;原文未提及其他局限。
对床旁实践的改变
- 对≥65岁目击心源性OHCA,可参考年龄分层的无血流时间阈值(65-74岁14分钟、75-84岁11分钟、85-94岁2分钟、≥95岁0分钟)评估良好神经结局概率是否低于1%,辅助复苏决策。
- 该阈值来自回顾性概率模型估计,不能作为前瞻性验证的决策 cutoff,也不应推广至非目击、非心源性或<65岁患者。
指南或共识出处
- All-Japan Utstein Registry(2010-2023年数据);原文未提及具体指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The burden of cardiogenic out-of-hospital cardiac arrest (OHCA) among older adults is increasing. No-flow time is a key determinant of prognosis, and the aging brain may be increasingly vulnerable to ischemic injury during this interval.
OBJECTIVE: To delineate the association between no-flow duration and outcomes in older adults with cardiogenic OHCA using dynamic probability curves.
DESIGN, SETTING, AND PARTICIPANTS: This nationwide, population-based, multicenter retrospective observational cohort study used data from the All-Japan Utstein Registry from January 1, 2010, through December 31, 2023. Participants included adults 65 years or older with witnessed cardiogenic OHCAs treated within Japan's nationwide emergency medical service (EMS) system. Data were analyzed from December 1, 2025, to July 7, 2026.
EXPOSURE: No-flow time, defined as the interval from witnessed arrest to initiation of cardiopulmonary resuscitation by EMS clinicians.
MAIN OUTCOMES AND MEASURES: The primary outcome was 30-day favorable neurologic outcome, defined as cerebral performance category of 1 or 2. Age-stratified dynamic probability curves were constructed for patients aged 65 to 74 years, 75 to 84 years, 85 to 94 years, and 95 years or older to describe the time-dependent likelihood of outcome according to no-flow duration. For each age group, the no-flow time at which the estimated probability fell below 1% with 95% CIs was identified.
RESULTS: Among 1 795 502 registry cases, 259 851 patients met the inclusion criteria. The median patient age was 82 (IQR, 75-88) years, 148 018 (57.0%) were male, and the median no-flow time was 11 (IQR, 8-15) minutes. Overall, 8711 patients (3.4%) achieved a 30-day favorable neurologic outcome. In all patients 65 years or older, the no-flow times at which the estimated probability of favorable neurologic outcome fell below 1% was 11 (95% CI, 11-11) minutes. Corresponding thresholds for favorable neurologic outcome was 14 (95% CI, 14-14) minutes for those aged 65 to 74 years, 11 (95% CI, 10-11) minutes for those aged 75 to 84 years, 2 (IQR, 0-4) minutes for those aged 85 to 94 years, and 0 (95% CI, 0-0) minutes for those 95 years or older.
CONCLUSIONS AND RELEVANCE: In this cohort study of older adults with cardiogenic OHCA, the no-flow time window compatible with an estimated probability of at least 1% for favorable neurologic outcome became progressively shorter with advancing age. These findings may inform resuscitation decision-making in aging populations.
参考来源
- Kishihara Y, Kashiura M, Yasuda H, et al. No-Flow Duration and Outcomes After Cardiogenic Out-of-Hospital Cardiac Arrest in Older Adults. JAMA Netw Open. 2026. PMID: 42678699. doi:10.1001/jamanetworkopen.2026.31343
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。